Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Titel:
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Auteur:
Mauro, Michael J. Minami, Yosuke Hochhaus, Andreas Lomaia, Elza Voloshin, Sergey Turkina, Anna Kim, Dong-Wook Apperley, Jane F. Cortes, Jorge E. Abdo, Andre Fogliatto, Laura Maria Kim, Dennis Dong Hwan le Coutre, Philipp Saussele, Susanne Annunziata, Mario Hughes, Timothy P. Chaudhri, Naeem Chee, Lynette García-Gutiérrez, Valentin Sasaki, Koji Boquimpani, Carla Kapoor, Shruti Espurz, Noemi Dhamal, Vishal Rea, Delphine